TYK2 Inhibition: Evolving Options in Psoriasis Care - Episode 7
Understanding the FDA-Approved TYK2 Inhibitor in Psoriasis
Published on:
It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!
Deucravacitinib, approved in 2022, was the first selective TYK2 inhibitor for moderate-to-severe psoriasis. Can you describe its mechanism of action?
What are your impressions of the recently published long-term data for deucravacitinib in plaque psoriasis, which demonstrated sustained efficacy and a consistent safety profile through five years of treatment?
How does this data influence your perception of its role in long-term disease management?
Which patients are ideal candidates for deucravacitinib?
